Object. The Il13ra2 gene is often overexpressed in brain tumors, making Il13ra2 one of the vaccine targets for immunotherapy of glioma. In this study, using a mouse glioma model, the authors tested the hypothesis that vaccination using dendritic cells transfected with Il13ra2 mRNA induces strong immunological antitumor effects.
M alignant gliomas are unusual, but are considered to be one of the most aggressive tumors among brain cancers. A malignant glioma of astrocytic origin can differentiate into a WHO Grade III anaplastic astrocytoma or a Grade IV GBM. 28 Over many years, no significant prolongation of survival has been achieved. The prognosis for patients with malignant glioma remains poor, in spite of gross resection by microsurgery with adjuvant radiotherapy and chemotherapy. 48, 54 The median survival of patients with anaplastic astrocytoma is about 2-3 years, and that of patients with GBM is only 9-12 months; 47 patients with GBM usually die within 2 years. The combination therapy of temozolomide with radiotherapy improved the survival time of patients with GBM by 2.5 months, but a complete cure has not been achieved. 29, 49, 50 Therefore, the development of new therapeutic strategies for malignant glioma is essential. Proposed investigations and ongoing clinical trials of immunotherapy have shown the effectiveness and possibility of clinical application of one of these new therapies, a dendritic cell-based vaccine, and many authors have reported the successful induction of tumor immunity by antitumor immune therapy in which dendritic cell-based vaccine therapies were used. 4, 12, 39, 51 A positive aspect of immunotherapy is that it selectively destroys tumor cells, and no apparent side effects are usuVaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in mice ally observed. Therefore, immunotherapy for malignant glioma could be an attractive supplemental and alternative therapeutic option.
The CNS is an immunologically privileged site hidden behind the blood-brain barrier. 53 Nevertheless, immune effector cells induced peripherally can be recruited into the CNS. 18, 20, 22 Malignant glioma cells are considered to be poor antigen-presenting cells to the immune system, because the B7 costimulatory molecules required for direct activation of T cells with tumor cells are downregulated and because the tumor itself secretes immunosuppressive cytokines and factors such as vascular endothelial growth factor. 34, 55 To induce an antitumor immune response against malignant glioma, professional antigen-presenting cells are needed to internalize and present malignant glioma antigens efficiently to immune cells. 56, 58, 59 In reported immunotherapies, dendritic cells have been used as antigen-presenting cells for the induction of efficient immune reaction. 1, 41 Various forms of tumor antigens have been applied to improve the induction of specific antitumor immune responses; for example, apoptotic tumor cells, tumor cell lysates, proteins, peptides, and nucleic acids. 5, 9, 32, 43, 45, 57 In our series, we used mRNA as a tumor antigen. The mRNA can be synthesized in vitro, transferred into dendritic cells, and subjected to molecular engineering. Furthermore, the mRNA is superior to cDNA in its transfection efficiency and safety, and is also superior to synthetic peptides, because there is no need to determine whether the peptides have been presented to the immune system. Interleukin-13 is an immunoregulatory cytokine secreted predominantly by activated Th2 cells and is one of the mediators in the pathogenesis of allergic inflammation. 3, 13, 16, 17, 19 The IL-13 receptor consists of IL4Ra, IL13Ra, and IL13Ra2. 3, 19 Over the past years, several studies revealed that Il13ra2 is highly and specifically overexpressed in high-grade gliomas, including GBM, whereas it is not expressed or is expressed at a very low level in the normal brain or low-grade gliomas. 8, 21, 25, 26, 33 In recent years, study results have proved that Il13ra2 is an effective antitumor vaccine target when used with antigen-presenting cells. 11, 23, 31 The cytotoxic T cells have a major role in immune reaction to tumor cells, and the activation of CD4+ helper T cells is essential for the induction of cytotoxic T cells in dendritic cell therapy. 40 To induce a strong immune response, it is necessary for antigen peptides to be presented not only on MHC class I but also on MHC class II molecules. 40, 41 Dendritic cells capture exogenous antigens, process in the endosomal pathway, and present on MHC class II molecules, leading to the induction of the CD4+ helper T-cell response. On the other hand, nuclear proteins are processed by degradation in proteasomes and are transported into the endoplasmic reticulum and then combined to form MHC class I molecules, which induce the CD8+ helper T-cell response.
14,27,35,37,41,52 Thus, effective transport of the Il13ra2 to both the MHC class I and class II molecules (cross-presentation) is very important to induce a strong immune response against malignant gliomas.
The purpose of the present study was to demonstrate the antitumor effects of vaccine therapy by using dendritic cells transfected with Il13ra2 mRNA. An SS and late endosomal/lysosomal sorting signal were attached to the Il13ra2 mRNA for efficient presentation of the antigen, not only on MHC class I molecules, but also on MHC class II molecules of dendritic cells, for cross-presentation.
Methods

Experimental Animals
Two hundred forty adult male C57BL/6 mice (6-8 weeks old) were purchased from Japan SLC Co., Ltd. Mice were maintained in a specific pathogen-free environment and provided with sterilized food and water. Mice weighing between 25 and 35 g were used in this study. This experiment was reviewed by the Committee on the Ethics of Animal Experiments at the Yamaguchi University School of Medicine and conducted under the Guidelines for Animal Experiments at the Yamaguchi University School of Medicine and the Law (no. 105) and Notification (no. 6) of the Japanese government.
Cell Lines
The KR158B cell is a subclone of the murine glioma cell line KR158, involving the mutation of 2 tumor suppressor genes, Nf1 and Trp53. 44 The KR158B glioma cells were cultured and maintained in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2 mM l-glutamine (complete media).
Polymerase Chain Reaction
The total RNA of the KR158B glioma cells was generated by RT-PCR. The cDNA was obtained from total RNA by using TRIzol (Invitrogen) according to the manufacturer's protocol.
Plasmid Cassette for RNA Transcription
Plasmid constructs were described previously. 2, 15 Briefly, for in vitro transcription, the plasmids were cloned with pSP64 vector (Promega). A TRP-2 SS fragment and TM-Cyto were amplified from TRP-2 cDNA by PCR (Ex Taq polymerase, Takara). The PCR products were cloned as a Hind III-Pst I SS fragment and BamH I-Sma I TMCyto fragment into pSP64 to allow in vitro transcription under the control of an SP6 promoter to transport the Il13ra2 protein efficiently to MHC class II compartments for eventual cross-presentation by both classes I and II on dendritic cells in a cognate manner.
In Vitro Transcription of mRNA
The full-length mouse Il13ra2 cDNA was generated by RT-PCR by using the following forward and reverse primers: mouse Il13ra2 forward primer, 5′-AAAAGTCG ACATGGCTTTTGTGCATATCAG-3′; and Il13ra2 reverse primer, 5′-AATCTAGAACAGAGGGTATCTTCAT AAGCA-3′. The products were cloned as a Sal I-IL13Rα2-Xba I fragment. The fragment was inserted into a pSP64 cassette (Fig. 1) . In vitro transcription was performed in a 60-µl reaction mix at 37°C for 2 hours by using an mMES-SAGE mMACHINE T7 ultra kit (Ambion).
Dendritic Cell Generation From Mouse Bone Marrow
The C57BL/6 mice (144 animals) were painlessly killed, and femurs and tibias were removed. The bone marrow was flushed with PBS by using a syringe with a 26-gauge needle, and then it was filtrated through a 70-µm cell strainer. The bone marrow cells were adjusted to 2 × 10 5 cells/ml in complete media and plated on 100-mm dishes. They were cultured for up to 7-10 days in the presence of 1000 U/ml of granulocyte-macrophage colony-stimulating factor and 500 U/ml of IL-4 at 37°C, in 5% CO 2 . On Day 4, the same amount of cytokines was added to the dishes. Seven to 10 days later, we obtained several immune cells, including dendritic cells. To isolate the dendritic cell population, we collected the cells in the dishes and suspended them in 5 ml of complete media. The same volume of 14.5% (weight/volume) metrizamide in complete media was underlain and centrifuged at 1200 G for 20 minutes at room temperature. After centrifugation, the cells in the interface (the dendritic cell population) were collected and washed with PBS. These dendritic cells were used for subsequent RNA transfection. Before and after RNA transfection, the expression of the surface molecules on the dendritic cells was analyzed with the aid of flow cytometry (Epics XL, Beckman Coulter Co.).
Transfection of mRNA to Dendritic Cells
The dendritic cells were resuspended and adjusted to 10 6 cells/5 ml in RPMI 1640. The RNA transfection was accomplished by mixing 10 6 dendritic cells and 10 µg of mRNA, using a TransMessenger Transfection Reagent (Qiagen), and incubated for 3 hours at 37°C. After transfection, the cells were washed with PBS and used for dendritic cell therapy.
Chloroquine Inhibition Assay
To assess the intracellular mechanisms of antigen processing to MHC class II compartments for eventual crosspresentation by both classes I and II on the dendritic cells in a cognate manner, we linked the leader sequence and the cytoplasmic domain containing a late endosomal/lysosomal sorting signal derived from the mouse TRP-2 gene to the Il13ra2 gene at its N 2 and COOH terminus, respectively. We investigated whether proteins translated from such mRNA constructs with a late endosomal/lysosomal sorting signal were actually localized and degraded in the human leukocyte antigen class II processing compartments. For this purpose, EGFP and TRP2-EGFP mRNAs were used. The TRP2-EGFP is a fusion mRNA in which EGFP was linked to the N 2 terminus region of TRP-2 at nucleotide position 169, as previously described. 15 After transfection of EGFP or TRP2-EGFP mRNA into dendritic cells, 50 µM of the lysosomal degradation inhibitor chloroquine was added to the dendritic cells immediately after mRNA transfection. The expression of EGFP was analyzed by flow cytometry. Dendritic cells were harvested at different time points after transfection and treated with DAKO Intrastain (DAKO). The EGFP was detected by anti-EGFP monoclonal antibody by using anti-mouse IgG-FITC, as described previously. 15 
Implantation of Tumor Cells Into the Mouse Brain
The mice were anesthetized with an intraperitoneal injection of pentobarbital sodium. The head skin was incised almost 20 mm, and a 1.5-mm bur hole was made on cranial bone 2 mm to the right of the bregma. The injection device consisted of a stereotactic frame composed of a 27-gauge needle that was connected via a catheter to a 10-µl Hamilton syringe. A total of 2 × 10 5 KR158B cells suspended in 2 µl PBS was injected into the brain over 10 minutes. The needle was held in the same place for 10 minutes and then retracted slowly over 5 minutes. Wound closure was performed with bone wax and sutures.
The tumor-implanted mice were divided into 2 groups. One group (80 animals) was allowed to live without a time limit to evaluate the survival time. The other group (16 animals) was scheduled to be killed on Day 20 after implantation for cell toxicity assays and histological and immunohistochemical examination.
Statistical Analyses
Survival data were calculated using the Kaplan-Meier method. Statistical significance of survival data between the groups was compared using a log-rank analysis. Differences at p < 0.05 were considered statistically significant.
Vaccination With Dendritic Cells
On Days 3 and 10 after tumor cell implantation, mice received immunization. Mice implanted with tumor cells were classified into 4 groups, as follows: the first group was injected intraperitoneally with 3 × 10 5 Il13ra2 mRNAtransfected dendritic cells; the second group was injected intraperitoneally with 3 × 10 5 chloroquine-treated dendritic cells after the Il13ra2 mRNA transfection; the third group was injected intraperitoneally with 3 × 10 5 PBS-pulsed dendritic cells without Il13ra2 mRNA; and the last group received no treatments after tumor cell implantation.
Immunocytochemical Examination for Il13ra2 and Immune Cells
On Day 20 after tumor cell implantation, some mice from all groups were killed for histological and immunohistochemical examination. Their brains were cut with a cryostat through the area of tumor implantation at a thickness of 10 µm, and the sections were either mounted on glass slides for routine histological staining with H & E or for immunohistochemical studies. The sections prepared for immunohistochemical studies were fixed in cold ethanol, treated with hydrogen peroxide, and blocked with 1.5% rabbit serum before being incubated overnight at room temperature with the rat monoclonal antibodies TIB122 (anti-CD45), KT3 (anti-CD3), YTA3.1 (anti-CD4), YTS169.4 (anti-CD8), FA/11 (macrosialin), and TIB222 (anti-CD25). After being washed by PBS, the sections were incubated with horseradish peroxidase-conjugated rabbit anti-rat IgG (DAKO) that had been adsorbed with murine serum. The sections cut for immunocytochemical testing for mouse Il13ra2 were also fixed with cold ethanol, treated with hydrogen peroxide, and blocked with 1.5% rabbit serum before being incubated overnight at room temperature with the goat polyclonal antibody for the mouse Il13ra2 (R and D Systems, Inc.). After washing with PBS, the sections were incubated with biotinylated rabbit anti-goat IgG for 30 minutes. After again being washed with PBS, the sections were incubated with VECTASTAIN ABC Reagent (VECTOR Laboratories, Inc.) containing Avidin DH and biotinylated horseradish peroxidase H reagent, which were especially prepared to form ideal complexes for immunoperoxidase staining. Horseradish peroxidase was detected with diaminobenzidine. The sections were counterstained with cresyl violet or hematoxylin, and then they were dehydrated and mounted.
Quantification of Infiltrating Cells
The number of CD8 and CD4 T cells seen in the Il13ra2-treated group was semiquantified. The infiltration pattern of T cells in the tumors was heterogeneous, and therefore the number of these T cells was counted in the infiltrating area. The degree of T-cell infiltration was graded as follows, 
Results
Expression of Il13ra2 mRNA and Il13ra2 in the KR158B Glioma Cell Line
To detect the Il13ra2 expression in the KR158B cell line, we examined the Il13ra2 mRNA expression by using conventional RT-PCR. We also examined Il13ra2 protein with immunohistochemical studies performed using the tumor-implanted mouse model. The results showed that Il13ra2 mRNA was expressed in the KR158B glioma cell line (data not shown). In the in vivo model, Il13ra2 protein was overexpressed on the cytoplasm of tumor cells, and its distribution was relatively homogeneous (Fig. 2A) . By contrast, in normal brain tissue Il13ra2 was not detected using immunohistochemical studies (Fig. 2B) .
Dendritic Cell Phenotype Before and After Il13ra2 mRNA Transfection
The expression of the surface molecules of the dendritic cells before RNA transfection was analyzed using flow cytometry. The dendritic cells showed CD11c+, CD40+, CD86+, H-2Kb+, I-Ab+, and DEC205+. After mRNA transfection, the results of the flow cytometry revealed no change in the dendritic cell phenotypes. Additionally, after chloroquine treatment, the phenotype of the Il13ra2 mRNA-transfected dendritic cells was analyzed using the same method.
Chloroquine Inhibition Assay
The EGFP linked to the targeting signal (TRP2-EGFP) was almost completely degraded in untreated dendritic cells at 72 hours after transfection. Because the degradation of unlinked EGFP was not inhibited by chloroquine addition, these data suggest that the EGFP containing the TRP-2 targeting sequence is transported to and degraded in the MHC class II processing compartments, as described previously. 15 After chloroquine treatment, the expression of the surface molecules on the Il13ra2 mRNAtransfected dendritic cells was analyzed by flow cytometry. The dendritic cell phenotypes after chloroquine treatment were the same as those before (data not shown).
Antitumor Effects of Dendritic Cells Transfected With Il13ra2 mRNA
The mice immunized with dendritic cells transfected with Il13ra2 mRNA survived significantly longer (mean survival 38.5 days, 20 animals) than did the mice immunized with nontransfected dendritic cells (mean survival 26.8 days, 20 animals; p = 0.0024, log-rank analysis of survival curves) and the animals without immunization (mean survival 23.5 days, 20 mice; p = 0.0003, log-rank analysis of survival curves) (Fig. 3) . In addition, the mice immunized with dendritic cells transfected with Il13ra2 mRNA survived significantly longer than did the ani- 
Immunocytochemical Analysis
Using H & E staining, we compared the intracranial tumor volumes among all 4 groups. We found that the tumor volumes in the mice vaccinated with dendritic cells transfected with Il13ra2 mRNA were smaller than those in the other groups, especially the group of nontreated mice ( Fig. 4A and B) .
Brain-infiltrating inflammatory cells in the intracranial implanted tumor revealed by immunocytochemical staining are shown in Fig. 5 . The upper panels (Fig.  5A-D) are photomicrographs from the group vaccinated with dendritic cells transfected with Il13ra2 mRNA, and the lower panels (Fig. 5E-G) are photomicrographs from the group with no treatment. In the group vaccinated with dendritic cells transfected with Il13ra2 mRNA, CD45+ leukocytes were detected within and around the tumors (Fig. 5A) . A greater number of CD3+ lymphocytes had infiltrated in and around the tumor (Fig. 5B) , and these lymphocytes contained not only CD8+ (Fig. 5C ) but also CD4+ (Fig. 5D) T cells. In contrast, also in the brains implanted with KR158B glioma cells from the group that received no treatment, CD45+ leukocytes were detected within and around the tumors (Fig. 5E) . However, the infiltrating cells were mainly macrophages (Fig. 5F ), and few CD3+ lymphocytes were present in the tumor or surrounding brain tissue (Fig. 5G) . In the group vaccinated with chloroquine-treated dendritic cells, only a few T lymphocytes were detected.
The degree of T-cell infiltration in the tumor is summarized in Table 1 . In the group treated with dendritic cells transfected with Il13ra2 mRNA, the degree of CD4+ and CD8+ T cells was +++, or at least ++. By contrast, in the untreated group, no CD4+ and CD8+ cells were detected.
Discussion
It has been reported that Il13ra2 protein could be an attractive vaccine target and that effective antitumor immune responses could be induced in preclinical models by using dendritic cell-based vaccines. 11, 24 Furthermore, it has been well documented that Il13ra2 antigen in HLA-A0201 CD8+ T cells could induce specific T-cell responses. 24 Therefore, the Il13ra2 could be an HLA-A0201-restricted cytotoxic T-cell antigen in immunotherapy of patients with malignant glioma. In this study, we used the full-length mouse Il13ra2 cDNA for the preparation of mRNA for Il13ra2. We had previously reported that mRNA induced cytotoxic T-cell activity in vitro by using the same vector, 15 and mRNA for Il13ra2 used in dendritic cell-based vaccines is thought to be immunogenic.
In recent studies it has been reported that the Il13ra2 chain is specifically overexpressed by glioblastomas, whereas normal brain cells do not express this protein, or express it at a very low level. 7, 8, 10, 11, 21, 25, 26, 33 The Il13ra2 chain was highly expressed in high-grade gliomas, but no or low-level expression was found in normal or low-grade glioma tissues. 60 In our mouse glioma model implanted with KR158B glioma cells, we confirmed Il13ra2 expression by immunohistochemical investigation, whereas Il13ra2 was not detected in the normal mouse brain. Moreover, we also examined the normal mouse brain tissues that had been immunized with Il13ra2 mRNA-transfected dendritic cells by using histological studies, and could not detect any toxicity. From these results, Il13ra2 seemed to be a suitable target as an antitumor antigen for vaccine therapy of glioma. However, it was reported that Il13ra2 is, in fact, expressed in only a subset of gliomas; probably a minority. 23 The previously reported data indicate that prescreening of subsets may be of benefit in future trials of Il13ra2-targeting immune therapies. In addition, the implication of cell-to-cell heterogeneity of the expression of this antigen is an important problem. Due to the antigenic heterogeneity among glioblastoma tumor cells, several peptides should be used to target a large number of tumor cells. With regard to the expression of Il13ra2 in other organs, it has been reported in the kidney, spleen, liver, lung, thymus, respiratory epithelium, and monocytes in humans. 19, 42 Therefore, significant toxicity might ensue in human models with specific targeting of this antigen. Although we did not find any toxicity based on our observations of the clinical features of the mouse models used in this study, there might be adverse effects that would be revealed by detailed microscopic observation of these organs. We should pay serious attention to the possibility of unexpected adverse effects caused by Il13ra2-targeting immune therapies in human clinical trials.
To induce a strong immune response, it is necessary for antigen peptides to be presented not only on MHC class I molecules, but also on MHC class II molecules. 40, 41 Presentation of antigen peptides on MHC class II molecules activates CD4+ T cells that release interferon-γ. In this study, we designed modified mRNA containing SS domain-and TM-Cyto domain-sorting signals of TRP-2 to the N 2 and COOH terminus of Il13ra2, and transfected it to dendritic cells. This is for effective transportation of the Il13ra2 to both the MHC class I and class II molecules, making it possible for the antigen to be cross-presented. We previously demonstrated that this unique strategy was useful for the efficient induction of specific immune responses. 2, 15 With regard to the timing of a vaccine therapy in this study, we followed the model of our studies published previously. 2, 15 We did not test the preventive effect of a vaccination, because it would not be practical when considering clinical application. According to a recent review by Nencioni et al., 36 most previous studies have used weekly, biweekly, or monthly injections with at least 2 vaccine administrations. It seems likely that several injections will be required to expand antigen-specific lymphocytes in vivo. It would have been interesting if we could have continued our weekly vaccination for a longer period, but the in vivo growth of KR158B was too fast for us to try it. Mice in the group vaccinated with dendritic cells transfected with Il13ra2 mRNA survived longer compared with mice in the untreated groups (Fig. 3) . This might show that the Il13ra2 peptides translated from mRNA would be effectively immunogenic and could be effective antitumor antigens. Moreover, in vaccination therapy for tumors, the immune response induced by dendritic cells transfected with mRNA has the potential to reduce tumor cell proliferation. Survival time was longer in the group treated with dendritic cells transfected with Il13ra2 mRNA than in the group of chloroquine-treated dendritic cells with the mRNA, as well as other control groups. Chloroquine is an inhibitor for lysosomal degradation and raises the pH in the endosomal and lysosomal compartments, inhibiting protein hydrolysis by cathepsins. 6, 30, 38, 46 Thus, it inhibits lysosomal degradation of antigen peptides and then suppresses their MHC class II presentation, giving rise to the decreased antitumor effects of dendritic cells. Our present results suggest that the efficient cross-presentation of antigen peptides plays an important role in the induction of a significant antitumor effect.
The tumor volume of the mice vaccinated with dendritic cells transfected with Il13ra2 mRNA tended to be smaller than that of the mice in other groups. This result indicates that vaccine therapy using Il13ra2 mRNAtransferred dendritic cells may suppress tumor growth. Immunohistochemical analysis revealed that greater numbers of CD3+ lymphocytes infiltrated the tumor tissues in the mice vaccinated with dendritic cells transfected with Il13ra2 mRNA compared with the mice in other groups, and that these lymphocytes contained not only CD8+ T cells but also CD4+ T cells. In contrast, in the mice vaccinated with chloroquine-treated dendritic cells and in the nontreated group, we detected mainly macrophages, with a few or no T cells. From these results we deduced that our vaccine therapy could activate T cells, and then induce specific immune responses to the tumor and antitumor effects.
Even in the group treated with dendritic cells transfected with Il13ra2, the survival time was still modest, and almost 90% of mice in this group finally died by 80 days after tumor implantation. Although Il13ra2 could be an effective immune target, the immunogenicity might not be strong enough to cure the mice receiving intracranial transplantation of KR158B cells. One possible explanation is the lower expression level of MHC class I and class II molecules on the surface of KR158B cells. 44 Additional strategies will be necessary to improve the therapeutic efficacy of mRNA-loaded dendritic cells in this tumor model.
Conclusions
Our study showed the immunotherapeutic potential of vaccine therapy with dendritic cells transfected with Il13ra2 mRNA in a mouse malignant glioma model. The results show that Il13ra2 mRNA may be one of the targets of vaccine therapy for malignant gliomas. This treatment could be a supplemental therapeutic arm for brain malignant glioma protocols. Additionally, with our presented method, it is possible that we could use other mRNAs together with Il13ra2 mRNA as target antigens, which might strengthen this therapeutic strategy.
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